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chylous effusion with a pleuroperitoneal window and omental flap
Subroto Paul, MD,a Stacey Su, MD,a Heather Edenfield, BA,a David J. Kwiatkowski, MD,b and
Raphael Bueno, MD,a Boston, MassLymphangioleiomyomatosis (LAM) is a rare progressive
cystic disease of the lung that predominantly affects women.
Clinical features of the disease include spontaneous pneu-
mothoracices, dyspnea, cough, as well as the formation of
chylous effusions. These effusions are often refractory to
treatment. We describe a case of a 74-year-old woman
with LAM associated chylous effusions that was refractory
to standard treatments including bowel rest with total paren-
tal nutrition (TPN), thoracic duct ligation, and pleurectomy
but was successfully managed with a novel combination of
oral progesterone, rapamycin, and doxycycline combined
with the creation of a pleuroperitoneal shunt with omental
flap placement in the pleural cavity.
CLINICAL SUMMARY
A 74-year-old woman presented with recurrent chyloper-
icardium and chylothorax. Thirty years earlier, she had 3 left
pneumothoraces treated by means of pleurodesis, with
findings of ‘‘blisters’’ on her lungs. At age 71 years, she
experienced abdominal discomfort, abdominal computed
tomographic scanning showed a complex retroperitoneal
infiltrative mass, and biopsy showed lymphangioma. Three
years later, she presented with dyspnea and was found to
have bilateral pleural effusions, a pericardial effusion, and
diffuse cystic parenchymal changes on chest computed to-
mographic scanning (Figure 1, A). Echocardiographic anal-
ysis revealed pericardial tamponade, which was drained for
600 mL of chyle. Her pericardial effusion recurred, and she
was referred for surgical intervention. Abdominal magnetic
resonance imaging showed a complex retroperitoneal mass
extending to the aortic bifurcation (Figure 1, B). Lymphan-
giographic analysis showed dilated torturous lymphatic
channels (Figure 1, C). Review of her previous abdominal
mass biopsy (Figure 1, D) confirmed lymphangioma. A
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lymphangioleiomyomatois (LAM) was made.
She underwent creation of a subxiphoid pericardial win-
dow and laparoscopic ligation of thoracic duct tributaries
in the retrocrural area. Bilateral chylous effusions worsened,
particularly on the right, given her previous left pleurodesis.
Drainage of 2 to 3 L/d chyle from the right pleural space per-
sisted despite treatment with total parenteral nutrition and
bowel rest. Subsequent right thoracotomy with pleurectomy,
talc poudrage, and mass thoracic duct ligature failed to pre-
vent recurrent chylothorax. Attempted thoracic duct cannu-
lation failed, and thoracic duct embolization could not be
performed.
The patient’s urine had increased levels of matrix metal-
loproteinases, and oral doxycycline was administered.
Based on preliminary reports of its benefit in LAM, oral ra-
pamycin was started (trough level, 7–15 ng/mL). Progester-
one (400 mg administered intramuscularly every month)
was added empirically, and she was re-fed the chylous chest
tube output to restore immune function.
Despite surgical and medical therapy, the chest tube
output remained high, requiring prolonged inpatient care.
She underwent creation of a transdiaphragmatic window
by means of laparoscopic resection of a portion of the dia-
phragm to the right of the crus and posterior to the liver.
An omental flap was placed into the right pleural space con-
necting the right pleural cavity to the peritoneum, with the
hope that the omentum might absorb chyle and maintain
the patency of the pleuroperitoneal channel. The patient
was maintained on a clear liquid diet and total parenteral nu-
trition. Chest tube and abdominal drain outputs decreased,
and tubes and drains were removed within 7 days. The pa-
tient was discharged on a regular diet. The patient continues
to do well 16 months afterward. Follow-up chest films show
minimal bilateral effusions. She continues on doxycycline
and rapamycin (goal trough levels, 3–5 ng/mL).
DISCUSSION
LAM chylous effusions are often refractory to medical
treatment and can be severely debilitating, leading to ca-
chexia, immunosuppression, and death. There is no standard
effective medical or surgical therapy for LAM-associated
chylothorax, particularly when pleurodesis fails.1 Our case
is the first to describe the successful treatment of a refractory
LAM-associated chylothorax using a combination of drugsardiovascular Surgery c Volume 138, Number 2 497
Brief Clinical ReportsFIGURE 1. A, Chest computed tomographic image demonstrating the presence of cystic lesions and increased interstitial markings. B, Abdominal magnetic
resonance images taken with the Fast Spin Echo (FSE) Fat Saturated (FS) T2 technique demonstrating a complex infiltrating mass surrounding the aorta,
inferior vena cava, and perinephric spaces. Lymphangioma appears white with this imaging technique and is highlighted with an asterisk. C, A lymphangio-
gram demonstrating a massively enlarged and tortuous thoracic duct and tributaries. D, High-power views of abdominal mass biopsy specimens demonstrat-
ing cells ranging in morphology from spindle shaped to epithelioid that occur in clusters, with many lymphatic channels lined by endothelial cells consistent
with a diagnosis of lymphangiomyoma.aimed at various aspects of the pathogenesis of this disease
combined with the creation of a pleuroperitoneal window
and an omental flap.
Although the benefit of drug treatment in this patient is
uncertain, we have continued them at present, given the
patient’s improvement and tolerance of this regimen.
Doxycycline has been shown to be inhibit matrix metallo-
proteinases in experimental models and appeared to have
benefit in previous patients with LAM.2 Rapamycin is
used because its target, mammalian target of rapamycin
complex 1 (mTORC1), is constitutively activated in LAM.
A recent publication indicates therapeutic promise for rapa-
mycin in LAM.3 Based on the discovery of estrogen recep-
tors in LAM cells, progesterone has been used to treat LAM.
However, clear evidence of its benefit is lacking,4 and in this
patient it was discontinued without any clinical effect.
Externalized pleuroperitoneal shunts have been described
as a method to control refractory chylous pleural effusions in
children. Device placements to prevent shunt closure are
rarely performed because these become clogged, infected,
or both. Omental flaps are used in the repair or prevention
of bronchopleural fistulae and empyema cavities. Only
a single report in Italian has previously described a similar498 The Journal of Thoracic and Cardiovascular Suprocedure: the placement of an intrathoracic omental flap to
successfully treat chylothorax after failed partial pleurectomy
in a patient with LAM.5 It is unclear whether the omental flap
assisted in controlling the effusion through active absorption
of fluid or by maintaining the patency of the pleuroperitoneal
shunt. There remains no clear mechanism for fluid absorption
attributed to the omentum.
Refractory chylothorax in patients with LAM remains
a challenge. As shown in this report, pleuroperitoneal shunt
creation with omental flap placement combined with multi-
drug therapy should be considered in the armamentarium for
this often desperate condition.
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